10/25/2024
Recent advancements in Alzheimer's disease treatment have shown promise in slowing the progression of the condition. Monoclonal antibodies such as Lecanemab and donanemab have been approved by the FDA for patients with mild Alzheimer's and mild cognitive impairment, targeting beta-amyloid plaques in the brain to prevent their clumping. Additionally, a novel approach using a molecular compound called 4-phenylbutyrate (PBA) has demonstrated the ability to reverse disease signs and improve memory function in preclinical studies. These developments represent a significant step forward in the ongoing battle against Alzheimer's disease.
disease, , neurology, associates
Advancements in Alzheimer's disease treatment have shown promise in slowing the progression of the condition. A significant step forward in the battle.